Heart Transplantation
Source : https://pubmed.ncbi.nlm.nih.gov/38256691/
Heart transplantation (HTx) remains the last therapeutic resort for patients with advanced heart failure. The present work is a clinically focused review discussing current issues in heart transplantation. Several factors...
Heart transplantation advances include xenotransplantation, hepatitis C donors, improved rejection monitoring, and novel immunosuppressants, enhancing outcomes for patients with advanced heart failure.
Exercise intolerance in heart failure with preserved ejection fraction: Causes, consequences and the journey towards a cure
Source : https://pubmed.ncbi.nlm.nih.gov/38063130/
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of all heart failure cases nationwide and continues to rise in its prevalence. The complex, multi-organ involvement of the...
HFpEF's complex pathophysiology involves both cardiac and non-cardiac factors. Improving vascular health through interventions could enhance outcomes, underscoring the need for an integrative approach to treatment.
Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38300391/
We will assess recent trials, including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF, and assess how these may influence current practice and future research. There are few data on which...
Fluid retention in heart failure (HF) is managed primarily with loop diuretics, needing updated research to optimize treatment strategies and improve guidelines.
Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials
Source : https://pubmed.ncbi.nlm.nih.gov/37986663/
Heart failure with preserved ejection fraction (HFpEF) is a group of clinical syndromes that exhibit a remarkably heterogeneous phenotype, characterized by symptoms and signs of heart failure, left ventricular diastolic...
HFpEF is a complex heart failure syndrome with limited drug therapies. Emerging device-based therapies show promise in improving symptoms and reducing readmissions.
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Source : https://pubmed.ncbi.nlm.nih.gov/38441940/
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF...
Guideline-directed medical therapy for heart failure may influence cancer incidence and outcomes. Future research should refine HF treatment strategies in the context of coexisting cancer.